Darolutamide antagonizes androgen signaling by blocking enhancer and super‐enhancer activation

Prostate cancer (PCa) is one of the most frequent tumor types in the male Western population. Early‐stage PCa and late‐stage PCa are dependent on androgen signaling, and inhibitors of the androgen receptor (AR) axis represent the standard therapy. Here, we studied in detail the global impact of daro...

Descripción completa

Detalles Bibliográficos
Autores principales: Baumgart, Simon J., Nevedomskaya, Ekaterina, Lesche, Ralf, Newman, Richard, Mumberg, Dominik, Haendler, Bernard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463324/
https://www.ncbi.nlm.nih.gov/pubmed/32333502
http://dx.doi.org/10.1002/1878-0261.12693

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463324/
https://www.ncbi.nlm.nih.gov/pubmed/32333502
http://dx.doi.org/10.1002/1878-0261.12693

Ejemplares similares